1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Human Microbiome Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Human Microbiome Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Human Microbiome Market Regional Analysis
6.2 North America Human Microbiome Market Revenue 2021-2031 (US$ Million)
6.3 North America Human Microbiome Market Forecast Analysis
7. North America Human Microbiome Market Analysis – by Type
7.1 Product
- 7.1.1 Overview
- 7.1.2 Product: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Software and Services
- 7.2.1 Overview
- 7.2.2 Software and Services: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. North America Human Microbiome Market Analysis – by Application
8.1 Therapeutics
- 8.1.1 Overview
- 8.1.2 Therapeutics: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Diagnostics
- 8.2.1 Overview
- 8.2.2 Diagnostics: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Research
- 8.3.1 Overview
- 8.3.2 Research: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. North America Human Microbiome Market Analysis – by Disease Type
9.1 Obesity
- 9.1.1 Overview
- 9.1.2 Obesity: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Diabetes
- 9.2.1 Overview
- 9.2.2 Diabetes: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Autoimmune Disorder
- 9.3.1 Overview
- 9.3.2 Autoimmune Disorder: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.4 Cancer
- 9.4.1 Overview
- 9.4.2 Cancer: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.5 GIT
- 9.5.1 Overview
- 9.5.2 GIT: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: North America Human Microbiome Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. North America Human Microbiome Market – North America Analysis
10.1 Overview
10.2 North America
- 10.2.1 North America Human Microbiome Market Breakdown, by Key
Country, 2024 and 2031 (%)
- 10.2.1.1 North America Human Microbiome Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 US:
North America Human Microbiome Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.1.1 US: North America Human Microbiome Market Breakdown, by Type
- 10.2.1.1.2 US: North America Human Microbiome Market Breakdown, by Application
- 10.2.1.1.3 US: North America Human Microbiome Market Breakdown, by Disease Type
- 10.2.1.2 Canada:
North America Human Microbiome Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.2.1 Canada: North America Human Microbiome Market Breakdown, by Type
- 10.2.1.2.2 Canada: North America Human Microbiome Market Breakdown, by Application
- 10.2.1.2.3 Canada: North America Human Microbiome Market Breakdown, by Disease Type
- 10.2.1.3 Mexico:
North America Human Microbiome Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.3.1 Mexico: North America Human Microbiome Market Breakdown, by Type
- 10.2.1.3.2 Mexico: North America Human Microbiome Market Breakdown, by Application
- 10.2.1.3.3 Mexico: North America Human Microbiome Market Breakdown, by Disease Type
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 MaaT Pharma
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Ferring Holdings SA
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 AOBiome Therapeutics Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Finch Therapeutics Group Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Seres Therapeutics Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Merck & Co Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Rebiotix, Inc.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Yakult Honsha Co., Ltd.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 IFF Nutrition & Biosciences
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Synthetic Biologics, Inc.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For North America Human Microbiome Market
